Compare · ASXC vs SYK
ASXC vs SYK
Side-by-side comparison of Asensus Surgical Inc. (ASXC) and Stryker Corporation (SYK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ASXC and SYK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK is the larger of the two at $114.80B, about 570.9x ASXC ($201.1M).
- SYK has hit the wire 8 times in the past 4 weeks while ASXC has been quiet.
- SYK has more recent analyst coverage (25 ratings vs 3 for ASXC).
- Company
- Asensus Surgical Inc.
- Stryker Corporation
- Price
- $0.35+0.84%
- $299.36-1.92%
- Market cap
- $201.1M
- $114.80B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- AMEX
- NYSE
- IPO
- News (4w)
- 0
- 8
- Recent ratings
- 3
- 25
Asensus Surgical Inc.
Asensus Surgical, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery in the United States, Europe, and Asia. It digitizes the interface between the surgeon and the patient to pioneer a new era of Performance-Guided surgery by unlocking clinical intelligence for surgeons to enable consistently superior outcomes and a new standard of surgery. The company's products include Senhance Surgical system, a multi-port robotic surgery system that allows up to four arms to control robotic instruments and a camera; and SurgiBot System, a single-port robotically enhanced laparoscopic surgical platform. Its products also comprise instruments; and Senhance ultrasonic system, an advanced energy device to deliver controlled energy to ligate and divide tissue. The company was formerly known as TransEnterix, Inc. and changed its name to Asensus Surgical, Inc. in February 2021. Asensus Surgical, Inc. was founded in 2006 and is based in Durham, North Carolina.
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Latest ASXC
- SEC Form 15-12G filed by Asensus Surgical Inc.
- SEC Form EFFECT filed by Asensus Surgical Inc.
- SEC Form EFFECT filed by Asensus Surgical Inc.
- SEC Form EFFECT filed by Asensus Surgical Inc.
- SEC Form EFFECT filed by Asensus Surgical Inc.
- SEC Form EFFECT filed by Asensus Surgical Inc.
- SEC Form S-8 POS filed by Asensus Surgical Inc.
- SEC Form S-8 POS filed by Asensus Surgical Inc.
- SEC Form S-8 POS filed by Asensus Surgical Inc.
- SEC Form S-8 POS filed by Asensus Surgical Inc.
Latest SYK
- VP, Chief Legal Officer Fletcher Robert S sold $1,394,409 worth of shares (4,544 units at $306.87) as part of a pre-agreed trading plan, decreasing direct ownership by 30% to 10,582 units (SEC Form 4)
- Director Stryker Ronda E sold $96,792,669 worth of shares (310,000 units at $312.23) (SEC Form 4)
- Stryker Launches Pangea Plating System and Completes First Case in Europe
- SEC Form SD filed by Stryker Corporation
- SEC Form 8-K filed by Stryker Corporation
- BioStar Capital-Backed Amplitude Vascular Systems' $835M Acquisition by Stryker Reflects Strength of Michigan's Medtech Ecosystem
- VP, Chief HR Officer Fink M Kathryn exercised 21,582 shares at a strike of $167.98, covered exercise/tax liability with 16,362 shares and sold $2,473,756 worth of shares (8,720 units at $283.69) (SEC Form 4)
- SEC Form 10-Q filed by Stryker Corporation
- Director Suri Rajeev was granted 762 shares, increasing direct ownership by 12% to 7,190 units (SEC Form 4)
- Director Stryker Ronda E was granted 762 shares, increasing direct ownership by 136% to 1,322 units (SEC Form 4)